UMDF Genetic Testing for Suspected Mitochondrial Disease Program
About this Program
Welcome to the UMDF Genetic Testing for Suspected Mitochondrial Disease Program, which is financially supported by Reneo Pharmaceuticals. This new, no cost genetic testing program is designed to aid clinicians in obtaining a molecular diagnosis for patients clinically suspected of having a primary mitochondrial disease (PMD). The testing program will run through MNG Laboratories and utilize their “Comprehensive Cellular Energetics Defects (NGS Panel and Copy Number Analysis + mtDNA)” test. This test covers 320 known pathogenic mutations in nuclear DNA plus full mitochondrial DNA sequencing, providing broad insights as to the underlying genetic disorder the patient may have.
This website provides easy instructions to ensure your genetic test request is correctly processed. You can read our brochure for more details.
This program is designed to provide clinicians an opportunity to order no-cost genetic testing for patients who have a suspected primary mitochondrial disorders (PMD) based on expert clinical evaluation. Our aim is to facilitate a diagnosis to aid in optimal clinical care and potential participation in clinical trials.
- Ordering clinician and patient must be based in the USA
- Patient must have a clinical diagnosis consistent with PMD
- Patient has never had whole exome or whole genome sequencing.
- Patients without insurance, or insurance that does not cover costs for such tests.
IMPORTANT: We ask that you ensure all insurance options have been exhausted prior to submitting a test request. Since many other disorders have clinical symptoms that overlap with PMD, and testing capacity is limited, please use discretion before ordering.
- Visit the MNG site to download the TRF and order testing kits. MNG offers two options for sample collection, either Blood Genetic Collection Kit or Buccal Swab Genetic Collection Kit. You may use either sample type when submitting an order. PLEASE NOTE: Up to 3 test kits of each sample type can be ordered at a time. Due to supply chain issues, please allow a 8-10 days for kit arrival via FedEx Ground. TRF can be filled out digitally, but needs to be printed for patient signature.
- Fully complete all sections of the TRF form. Print a copy and complete signatures from physician and patient.
- Patient must read and sign the consent.
- Collect sample and place sample, completed TRF and patient consent in the return postage paid test kit box.
- Test results will be provided in 4 to 6 weeks. We would encourage you to allow at least 6 weeks for patient follow-up.
Before you send checklist
All of the following are encouraged to be included with test orders:
→ All specimens that will be analyzed
→ Completed Clinical Information
→ Informed Consent for Genetic Testing shared with patient and attestation signed (page 1)
Failure to follow the directions above, including returning incomplete forms, may delay your test request and/or potentially lead to cancellation of the order.
Remember, UMDF is here you support you and your patient.
UMDF has a number of resources to help patients find applicable clinical trials, attend a support meetings, find educational materials, and more. If you or a patient have a need, we encourage you to reach to firstname.lastname@example.org.
Frequently Asked Questions
What is the goal of this UMDF-sponsored genetic testing program?
What form of genetic testing is being provided in this program?
Who can request this genetic test?
Any U.S.-based healthcare provider can order for any U.S.-based patient(s) clinically suspected of primary mitochondrial disease can order this test.
Can patients submit a test request?
Who can I contact if I have general questions about the program?
Who can I contact if I have a question about the test provided or a specific order?
Is there any cost associated with this program?
How will patient information be used?
Who is eligible to participate in this program?
In order to participate, both the clinician as well as the patient must reside in the United States. The patient must have a clinical presentation that is consistent with primary mitochondrial disease and not previously had whole exome or whole genome sequencing. Lastly, all other options for paying for the genetic test should be exhausted prior to submitting a test request.